Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib ; volume:26 ; number:1 ; day:27 ; month:8 ; year:2024 ; pages:1-12 ; date:12.2024
Arthritis Research & Therapy ; 26, Heft 1 (27.8.2024), 1-12, 12.2024
- Urheber
-
Hetland, Merete Lund
Strangfeld, Anja
Bonfanti, Gianluca
Soudis, Dimitrios
Deuring, J. Jasper
Edwards, Roger A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-024-03376-9
- URN
-
urn:nbn:de:101:1-2411130738036.155066364548
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Hetland, Merete Lund
- Strangfeld, Anja
- Bonfanti, Gianluca
- Soudis, Dimitrios
- Deuring, J. Jasper
- Edwards, Roger A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis
Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis
Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis
Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis